1-2 of 2
Panayiotis Panayiotidis
Close
Sort by
Journal Articles

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi-Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaidano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jaksic, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Vladimir Strugov, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Kostas Stamatopoulos, Lydia Scarfò, Richard Rosenquist, Paolo Ghia
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2794–2806.
https://doi.org/10.1182/bloodadvances.2022008821
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Clinical Trials & Observations
Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro, Don Stevens, David Trevarthen, Florian Hiemeyer, Jose Garcia-Vargas, Barrett H. Childs, Pier Luigi Zinzani, Martin Dreyling
Journal: Blood Advances
Blood Adv (2021) 5 (3): 823–828.
https://doi.org/10.1182/bloodadvances.2020002910
Published: 2021
Includes: Supplemental data